The concomitant use of VYVANSE and CYP2D6 inhibitors may increase the exposure of dextroamphetamine, the active metabolite of VYVANSE compared to the use of the drug alone and increase the risk of serotonin syndrome. Behavioral changes can offer valuable insight into whether a Vyvanse dose is too high. If you https://camillae256efs3.dgbloggers.com/profile